One Dintwe
Overview
Explore the profile of One Dintwe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Church E, Bishop E, Fiore-Gartland A, Yu K, Chang M, Jones R, et al.
Immunohorizons
. 2024 Sep;
8(9):695-711.
PMID: 39283647
Cutaneous mycobacterial infections cause substantial morbidity and are challenging to diagnose and treat. An improved understanding of the dermal immune response to mycobacteria may inspire new therapeutic approaches. We conducted...
2.
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, et al.
EBioMedicine
. 2024 Sep;
108:105320.
PMID: 39236556
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based...
3.
Garrett N, Dintwe O, Monaco C, Jones M, Seaton K, Church E, et al.
J Acquir Immune Defic Syndr
. 2024 Jun;
96(4):350-360.
PMID: 38916429
Background: An effective vaccine is required to end the HIV pandemic. We evaluated the safety and immunogenicity of a DNA (DNA-HIV-PT123) vaccine with low- or high-dose bivalent (TV1.C and 1086.C...
4.
Chirenje Z, Laher F, Dintwe O, Muyoyeta M, deCamp A, He Z, et al.
J Infect Dis
. 2023 Oct;
230(2):e405-e415.
PMID: 37795976
Background: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent...
5.
Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, et al.
J Infect Dis
. 2022 Jun;
226(2):246-257.
PMID: 35758878
Background: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates...
6.
Moodie Z, Walsh S, Laher F, Maganga L, Herce M, Naidoo S, et al.
PLoS Med
. 2020 May;
17(5):e1003117.
PMID: 32442195
Background: DNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in...
7.
Bekker L, Dintwe O, Fiore-Gartland A, Middelkoop K, Hutter J, Williams A, et al.
EClinicalMedicine
. 2020 May;
21:100313.
PMID: 32382714
Background: Tuberculosis (TB) remains the leading cause of infectious disease-related death. Recently, a trial of BCG revaccination and vaccination with H4:IC31, a recombinant protein vaccine, in South African adolescents (Aeras...
8.
Zhao L, Fiore-Gartland A, Carpp L, Cohen K, Rouphael N, Fleurs L, et al.
PLoS One
. 2020 Jan;
15(1):e0226803.
PMID: 31999736
Background: HIV vaccine trials routinely measure multiple vaccine-elicited immune responses to compare regimens and study their potential associations with protection. Here we employ unsupervised learning tools facilitated by a bidirectional...
9.
Dintwe O, Rohith S, Schwedhelm K, McElrath M, Andersen-Nissen E, De Rosa S
Cytometry A
. 2020 Jan;
97(2):199-201.
PMID: 31989802
No abstract available.
10.
Hosseinipour M, Innes C, Naidoo S, Mann P, Hutter J, Ramjee G, et al.
Clin Infect Dis
. 2020 Jan;
72(1):50-60.
PMID: 31900486
Background: The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in the context of different...